S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
S&P 500   5,130.95 (-0.12%)
DOW   38,989.83 (-0.25%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)

Freeline Therapeutics (FRLN) Earnings Date, Estimates & Call Transcripts

$6.48
0.00 (0.00%)
(As of 02/20/2024)

Earnings Summary

Upcoming
Earnings Date
Apr. 2Estimated
Actual EPS
(Dec. 1)
-$0.18 Beat By $0.06
Consensus EPS
(Dec. 1)
-$0.24
Skip Charts & View Estimated and Actual Earnings Data

FRLN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FRLN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Freeline Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.96)($0.04)($0.50)
Q2 20242($0.99)($0.04)($0.52)
Q3 20242($0.53)($0.04)($0.29)
Q4 20242($0.54)($0.04)($0.29)
FY 20248($3.02)($0.16)($1.59)

FRLN Earnings Date and Information

Freeline Therapeutics last released its quarterly earnings results on December 1st, 2023. The reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $0.01 million for the quarter. Freeline Therapeutics has generated ($5.59) earnings per share over the last year (($5.59) diluted earnings per share). Earnings for Freeline Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.15) per share. Freeline Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, April 2nd, 2024 based off prior year's report dates.

Freeline Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
4/2/2024
Estimated)
------- 
12/1/2023Q3 2023($0.24)($0.18)+$0.06($0.18)-$0.01 million
8/15/2023Q2 2023($3.62)($0.21)+$3.41($0.21)-$0.62 million
5/30/2023Q1 2023($1.64)($0.29)+$1.35($0.60)--
4/4/2023Q4 2022-($5.25)($5.25)($0.35)--
11/15/2022Q3 2022($6.45)($3.00)+$3.45($0.20)--
8/9/2022Q2 2022($8.10)($4.80)+$3.30($0.32)--
5/10/2022Q1 2022($8.70)($9.45)($0.75)($0.63)--    
3/31/2022Q4 2021($10.80)($14.55)($3.75)($0.97)--
11/9/2021Q3($15.1950)($12.90)+$2.2950($0.86)--
8/16/2021Q2 2021($13.95)($16.80)($2.85)($1.12)--
5/16/2021Q1 2021($11.70)($14.70)($3.00)($0.98)--












Freeline Therapeutics Earnings - Frequently Asked Questions

When is Freeline Therapeutics's earnings date?

Freeline Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, April 2nd, 2024 based off last year's report dates. Learn more on FRLN's earnings history.

Did Freeline Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Freeline Therapeutics (NASDAQ:FRLN) reported ($0.18) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.24) by $0.06. Learn more on analysts' earnings estimate vs. FRLN's actual earnings.

How much profit does Freeline Therapeutics generate each year?

Freeline Therapeutics (NASDAQ:FRLN) has a recorded net income of -$88.97 million. FRLN has generated -$5.59 earnings per share over the last four quarters.

What is Freeline Therapeutics's EPS forecast for next year?

Freeline Therapeutics's earnings are expected to grow from ($1.01) per share to ($0.15) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:FRLN) was last updated on 3/4/2024 by MarketBeat.com Staff